Biology subjects

Gregory, K. J.

Publications and source records attributed to Gregory, K. J..

6 recordsLinked to original sources

bioRxiv2026

Targeting of subcellular metabotropic glutamate receptor 5 signaling to modulate pain transmission

Metabotropic glutamate receptor 5 (mGlu5) is a class C GPCR crucial for neuronal development and synaptic transmission. mGlu5 is a potential therapeutic target in pain management and modulates pain-associated gene expression and signaling pathways. Although mGlu5 inhibitors have shown promise in treating pain, none have translated to the clinic. Up to 90% of neuronal mGlu5 expression is intracellular, although the precise locations and function of different mGlu5 intracellular pools remains unclear. Building on recent evidence showing the importance of endosome-mediated nociceptive signaling by other GPCRs, we hypothesized that endosomal pools of mGlu5 contribute to pain transmission, and that targeted inhibition of intracellular mGlu5 signaling results in superior analgesia. Using calcium mobilization assays and genetically encoded resonance energy transfer biosensors, we report that upon its activation mGlu5 recruits Gq/11 and Gs to the plasma membrane. Conversely, internalized mGlu5 in endosomes recruits only Gq/11 proteins. mGlu5 signaling is highly dependent on receptor trafficking to endosomes, with sustained nuclear ERK1/2 signaling requiring both receptor internalization and active glutamate transport into the cell. We generated pH responsive nanoparticles loaded with the mGlu5 negative allosteric modulator VU0366058 (DIPMA-VU058), enabling endosome-targeted inhibition of mGlu5. Nanoparticle encapsulation of VU0366058 enhanced inhibition of both acute and sustained nuclear ERK1/2 signaling, and significantly reduced neuronal excitability in nociceptive circuits in spinal cord slices from rats with neuropathic pain. Intrathecal administration of DIPMA-VU058 achieved superior analgesia in both inflammatory and neuropathic models of pain in mice compared to free VU0366058 and the reference compound fenobam. These studies demonstrate the importance of endosome-associated receptors for the complete mGlu5 signaling response. Furthermore, we show that manipulating the cellular distribution of an allosteric modulator can engender location-biased pharmacological effects. Together, we have revealed new and unappreciated roles for endosome-specific mGlu5 signaling and demonstrate that endosome-selective targeting may offer an alternative therapeutic approach for modulating mGlu5 activity.

pharmacology and toxicology↗

bioRxiv2024

Pharmacological characterisation of allosteric modulators at human mGlu5

The metabotropic glutamate receptor 5 (mGlu5) is a Class C G protein-coupled receptor, ubiquitously expressed throughout the CNS. With major roles in cognition, learning and memory, mGlu5 dysfunction is linked with numerous neurodegenerative and neuropsychiatric disorders, presenting a viable therapeutic target. Allosteric modulators bind topographically distinct sites from glutamate and other orthosteric agonists and enhance (positive allosteric modulators, PAMs), inhibit (negative allosteric modulators, NAMs) or do not effect (neutral allosteric ligands, NALs) mGlu5 function. While mGlu5 modulators have efficacy in in vivo rodent models of CNS disorders, none have made it to the clinic. We hypothesise this lack of translatability is arises from preclinical optimisation using on non-human pharmacological data, as functional studies are predominantly performed using rat mGlu5 and non-human brain neuronal cultures. Here we assess and quantify the impact of eleven chemically and pharmacologically diverse mGlu5 PAMs, NAMs and NALs on human mGlu5 activity using radioligand binding, iCa2+ mobilisation and IP1 accumulation assays. By comparing to published and newly generated data for rat mGlu5 we show that while modulator pharmacology is relatively consistent across species, ligand dependent species differences in allosteric modulator affinity, cooperativity and probe dependence are evident. Additionally, we report PAM-dependent effects on orthosteric agonist kinetic profiles at human mGlu5. Together, these data highlight the importance of systematic evaluation of mGlu5 allosteric ligand activity at human mGlu5 to improve drug design and overcome potential barriers to translatability to clinical settings.

pharmacology and toxicology↗

bioRxiv2024

Mapping the impact of DUSP6 in an ADHD iPSC derived-dopaminergic neuronal model

Although the gene DUSP6 has been implicated as a risk gene for attention deficit hyperactivity disorder (ADHD) in recent GWAS studies, its functional role in the aetiology of the condition remains poorly understood. DUSP6 is reported to regulate dopaminergic neurotransmission by decreasing available synaptic dopamine, suggesting a potential mechanism by which DUSP6 may confer risk to ADHD. In this study, we employed CRISPR-Cas9 to generate isogenic iPSC lines from an individual with ADHD, including heterozygous and homozygous DUSP6 knockouts alongside the parental control. These iPSC lines were differentiated into dopaminergic neurons and assessed at both cellular, and transcriptomic levels. We observed significant increase in extracellular dopamine in proportion to DUSP6 gene dosage, with greater elevation in homozygous compared to heterozygous knockouts. RNA sequencing further supported this finding, showing that DUSP6-knockout increased expression of genes regulating dopamine secretion and synaptic processes critical for dopaminergic system. Beyond dopamine signalling, transcriptomic changes implicated DUSP6 in neurodevelopmental biological mechanisms, essential to the development of ADHD. Furthermore, we identified significant overlaps between DUSP6-regulated genes and those associated with major depression, bipolar disorder, and schizophrenia, suggesting shared genetic pathways potentially influenced by DUSP6. This study provides mechanistic insights into the role that DUSP6 could potentially play in the aetiology of ADHD and its broader implications across related neuropsychiatric conditions.

neuroscience↗

bioRxiv2024

Transcriptome profiling of dopaminergic neurons derived from an ADHD induced pluripotent stem cell (iPSC) model

The most recent ADHD-GWAS meta-analysis highlighted the potential role of 76 genes enriched among genes expressed in early brain development and associated with midbrain dopaminergic neurons. However, the precise functional importance of the GWAS-identified single nucleotide polymorphisms (SNPs) remain unknown. In contrast to GWAS, transcriptome analysis directly investigates gene products by assessing the transcribed RNA. This allows one to gain functional insights into gene expression paving the way for a better understanding of the molecular risk mechanisms of conditions, such as ADHD. In this study, we performed transcriptome profiling of highly homogeneous dopamine neurons developed from induced pluripotent cells (iPSCs) that were derived from an individual with ADHD and a neurotypical comparison individual. Comparative gene expression analysis between the examined lines revealed that the top differentially expressed genes (DEGs) were predominantly associated with nervous system functions related to neuronal development and dopaminergic regulation. Notably, 29 of the DEGs overlapped with those identified by ADHD-GWAS meta- analysis. These genes are overrepresented in biological processes including developmental growth regulation, axonogenesis, and nervous system development. In addition, gene set analysis revealed significant enrichment for meta categories such as ion channel activity, synaptic function and assembly, neuronal development and cell differentiation. Further, we observed significantly reduced projections in the ADHD dopamine neurons at the mid- differentiation stage (day 14 in vitro), providing preliminary support for the delayed neuronal maturation hypotheses of ADHD. This study underscores the potential of using iPSC-derived cell type-specific models that integrate genome and transcriptome analyses for biological discovery in ADHD.

neuroscience↗

bioRxiv2023

SCA44- and SCAR13-associated GRM1 mutations affect metabotropic glutamate receptor 1 function through distinct mechanisms

Metabotropic glutamate receptor 1 (mGlu1) is a promising therapeutic target for neurodegenerative CNS disorders including spinocerebellar ataxias (SCAs). Clinical reports have identified naturally-occurring mGlu1 mutations in rare SCA subtypes and clinical symptoms of mGlu1 mutations have been described. However, how mutations alter mGlu1 function remains unknown. We explored SCA-associated mutation effects on mGlu1 cell surface expression and canonical signal transduction. Orthosteric agonists and positive allosteric modulators (PAMs) and negative allosteric modulators (NAMs) were assessed at two functional endpoints (iCa2+ mobilisation and IP1 accumulation). mGlu1 mutants exhibited differential impacts on receptor expression, with a truncating C-terminus mutation significantly reducing mGlu1 expression. Mutations differentially influenced orthosteric ligand affinity, efficacy, and functional cooperativity between allosteric and orthosteric ligands. Loss-of-function mutations L454F and N885del reduced orthosteric affinity and efficacy, respectively. Gain-of-function Y792C mutant mGlu1 displayed enhanced constitutive activity in IP1 assays, which manifested as reduced orthosteric agonist activity. mGlu1 PAMs restored glutamate potency in iCa2+ mobilisation for loss-of-function mutations, and mGlu1 NAMs displayed enhanced inverse agonist activity at Y792C relative to wild-type mGlu1. Collectively, these data highlight distinct mechanisms by which mGlu1 mutations affect receptor function and show allosteric modulators may present a means to restore aberrant mGlu1 function in rare SCA subtypes.

pharmacology and toxicology↗

bioRxiv2021

Dynamics of GLP-1R peptide agonist engagement are correlated with kinetics of G protein activation

The glucagon-like peptide-1 receptor (GLP-1R) has broad physiological roles and is a validated target for treatment of metabolic disorders. Despite recent advances in GLP-1R structure elucidation, detailed mechanistic understanding of how different peptides generate profound differences in G protein-mediated signalling is still lacking. Here we have combined cryo-electron microscopy, molecular dynamics simulations, receptor mutagenesis and pharmacological assays, to interrogate the mechanism and consequences of GLP-1R binding by four peptide agonists; glucagon-like peptide-1, oxyntomodulin, exendin-4 and exendin-P5. These data revealed that distinctions in peptide N-terminal interactions and dynamics with the GLP-1R transmembrane domain are reciprocally associated with differences in the allosteric coupling to G proteins. In particular, transient interactions with residues at the base of the binding cavity correlate with enhanced kinetics for G protein activation, providing a rationale for differences in G protein-mediated signalling efficacy from distinct agonists.

biochemistry↗